Overview

Prospective Study of Stereotactic Radiology Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:
0

Participant gender:
All

Summary

This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Henry Ford Health System

Treatments:

Bevacizumab
Carboplatin
Etoposide
Irinotecan
Temozolomide

Criteria

Inclusion Criteria: 1)Histologically proven intracranial glioblastoma multiforme. There
must be pathologic or imaging confirmation of tumor progression or regrowth after failure
of two previous treatment regimens 2) Patients will be eligible if the original histology
was low-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made 3)
History and physical exam, including neurologic examination within 4 weeks prior to
registration -

Exclusion Criteria: Warfarin or LMW heparin patients must have no active bleeding or
pathological condition that carries a high risk of bleeding

-